Moxonidin Al (Moxonidine)

Moxonidine selectively activates imidazoline I1 receptors in the brainstem, which diminishes sympathetic nervous system activity. This leads to reduced release of norepinephrine, lower heart rate, and decreased peripheral vascular resistance, collectively resulting in a drop in arterial blood pressure.

The dosage of Moxonidin Al is determined by the prescribing healthcare professional based on the individual’s blood‑pressure response, age, renal and hepatic function, and any concomitant medications. The prescriber will select the appropriate starting dose and any necessary adjustments.

The safety of moxonidine in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To request Moxonidin Al, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, which lowers blood pressure by reducing sympathetic outflow. Unlike ACE inhibitors or calcium‑channel blockers, it does not directly affect the renin‑angiotensin system or calcium channels, offering an alternative mechanism that can be useful when patients are intolerant to other classes.

Store Moxonidin Al tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Moxonidin Al is taken orally as a tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food. Follow the dosing schedule prescribed by the healthcare professional.

Serious adverse events, although rare, include severe hypotension, marked bradycardia, significant liver enzyme elevations, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, jaundice, or skin rash.

Moxonidin Al should be avoided in individuals with known hypersensitivity to moxonidine, severe hepatic impairment, or in pregnant women unless the benefit outweighs the risk. Caution is also advised for patients with uncontrolled heart‑rate disorders or those taking multiple central antihypertensive agents.